Approximately 40% of patients with Alzheimer’s disease suffer from psychotic symptoms, including hallucinations and delusions. There are currently no approved therapies for the treatment of psychosis in these patients. Meridien Research is conducting a study of an investigational medication designed to aid with these symptoms. To qualify, individuals must:
- Be 50+ years of age
- Have Alzheimer’s disease
- Be experiencing psychotic episodes (visual and/or auditory hallucinations, and/or delusions)
- Have a study partner knows the individual well
Eligible participants will receive study-related care, monitoring and study drug or placebo. Reimbursement for travel will be available to participants and their caregivers who qualify. All studies administered by a board certified physician. For more information, please call 727-347-8839 or complete the form below.